BioCentury | Apr 14, 2020
Finance

Blackstone makes largest-ever life sciences investment in Alnylam

Blackstone’s $2 billion investment in Alnylam is a departure from its other life sciences investments in size and scope, but the deal still fits the investor’s core model of focusing on products rather than companies....
BC Extra | Nov 22, 2019
Company News

Alnylam outlines ambitions, pipeline progress at R&D day

In its R&D day presentation Friday, Alnylam outlined its goals of becoming a self-sustaining company with at least eight approved drugs and 10 late-stage clinical candidates by 2025, with safer GalNAc conjugates, a late-stage amyloidosis...
BC Extra | Nov 19, 2018
Preclinical News

RNAi method targets placenta directly to treat preeclampsia

In a Nature Biotechnology study , researchers from University of Massachusetts Medical School and colleagues reported that siRNA targeting sFLT1 could help treat preeclampsia. The results suggest the RNAi modality could be used to directly target...
BC Innovations | Jun 23, 2016
Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
BC Innovations | Apr 21, 2016
Product R&D

A1M for preeclampsia

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy...
BC Week In Review | Dec 15, 2014
Company News

Alnylam pharmaceuticals news

Alnylam outlined plans to focus its RNAi pipeline on genetic medicine, cardio-metabolic diseases and hepatic infectious diseases. Clinical genetic medicine programs include Phase III transthyretin-mediated amyloidosis (ATTR) candidates patisiran and revusiran as well as Phase...
BC Innovations | Oct 16, 2014
Targets & Mechanisms

Alnylam interrupts preeclampsia

Preeclampsia often involves overactivation of the renin-angiotensin system that regulates blood pressure, but inhibiting the pathway is not possible because it would be toxic to the fetus. Alnylam Pharmaceuticals Inc. has developed an siRNA conjugate...
BC Week In Review | Oct 6, 2014
Clinical News

Alnylam preclinical data

In a rat model of preeclampsia, subcutaneous ALN-AGT led to >90% knockdown of maternal angiotensinogen (AGT) in the liver with no detectable evidence of fetal drug exposure. ALN-AGT also significantly reduced mean arterial blood pressure...
Items per page:
1 - 8 of 8